Objective: To evaluate whether clinical pharmacist's interventions have any impact on medication adherence of patients having inflammatory bowel disease and to assess the awareness of patients about their disease and the significance of medications they use. Materials and Methods: A prospective, interventional follow up study was conducted in the outpatients visiting Gastroenterology and Hepatology department of Amrita Institute of Medical Sciences, Kochi. To assess the level of medication adherence and patient's awareness, MMAS-8 and CCKNOW has been utilized. Once this baseline information's were collected, counselling was given to patients and they were supplemented with pill cards and patient information leaflets as educational material. During the follow up visit, all the above parameters were reassessed and compared with the baseline visit. Result: About 110 IBD patients have participated in this study. In baseline visit, 6.36% patients had low adherence, 62.73% patients had medium adherence, 30.91% patients had high adherence. During follow up visit, after intervention by clinical pharamcist, 3.64% patients had low adherence, 18.18% patients had medium adherence and 78.18 % patients had high adherence. From this study, it was notified that the average score of CCKNOW was only 8.15 in the beginning. Later on, it was escalated to 11.65 during the revisit periods. Conclusion: Knowledge of patients about their disease and medications were insufficient during baseline visit. Adherence to medication was found to be poor among IBD patients. Counselling provided by clinical pharmacist about the importance of medication adherence and provision of information leaflets and pill cards lead to an improvement in medication adherence and knowledge of IBD patients. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Hydroxyurea is an anti cancer chemotherapeutic drug .For high risk patients of essential thromocytosis (ET) , interferon and hydroxyurea are available agents in India to reduce their platelet count .Interferon is not an attractive agent due to its parentral mode of delivery and systemic side effects. Here, we aim to evaluate the efficacy of hydroxyurea in these subset of patients to normalize their platelet counts.This Retrospective study was conducted in the department of medical oncology and hematology at Amrita institute of medical science. We collected the data by reviewing the electronic medical records of the patients with ET in which 23 patients were seen to be at high risk for thrombotic events ,Out of these 23 high risk patients 17 were females and 6 were males and belonged to the mean age of 55.17 years.We found that 37.5 % showed complete response, 41.67 % showed partial response and 16.67 % showed no response. From this study we could observe that only 80% of patients benefited from hydroxyurea therapy and there is unmet need for an oral cytoreductive agent with good safety profile in ET . ABS019
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.